Home›Trial›NCT06448793
NCT06448793Completed

Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments

Study Summary

The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions / Drugs
Approved Non-small Cell Lung Cancer (NSCLC) therapies
View on ClinicalTrials.gov ↗
Sponsor
BMY
Bristol-Myers Squibb
Oncology
C51/100
Study Details
Enrollment650 participants
Primary Completion2025-10-31
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-10-14
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

This trial has completed. Results may be available via ClinicalTrials.gov or peer-reviewed publications.

Primary completion: 2025-10-31
Enrolled: 650 participants
Sponsor Catalyst Profile

Bristol-Myers Squibb (BMY) is the sponsoring company for this trial. BiotechSign currently grades this company C (51/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

BMY Full Pipeline →All Companies →
Other Trials from Bristol-Myers Squibb
NCT07215962Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non…NCT05489705A Prospective Registry Study to Assess Real-world Patient Characteristics, Treat…NCT07063342A Study to Evaluate Novel KarX and KarT Prototypes Versus the KarXT and KarX-EC …(PHASE1)NCT06937229A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agi…(PHASE3)NCT06003426A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part…(PHASE3)
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.
© 2026 BiotechSign — AI-powered biotech catalyst intelligence